Welcome to our dedicated page for Zenas BioPharma SEC filings (Ticker: ZBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zenas BioPharma, Inc. (Nasdaq: ZBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zenas is a clinical-stage global biopharmaceutical company focused on therapies for autoimmune diseases, and its filings document key aspects of its business, including stock exchange listing details, financing arrangements, licensing agreements and clinical development updates.
Recent Form 8-K filings describe material events such as the revenue participation and funding agreement with Royalty Pharma related to obexelimab, under which Royalty Pharma will provide up to $300 million in consideration in exchange for specified royalty and revenue participation rights. Other 8-Ks detail the license agreement with InnoCare Pharma granting Zenas exclusive rights to develop, manufacture and commercialize orelabrutinib in the multiple sclerosis field globally and non-oncology indications outside certain territories, as well as rights to ZB021 and ZB022. Additional current reports cover private placement financings, adoption of the 2026 Inducement Plan for equity awards, and press releases furnishing quarterly financial results.
Through this page, users can review how Zenas reports its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ZBIO, and the terms of material definitive agreements that shape its capital structure and pipeline strategy. Filings linked here include exhibits such as inducement equity plans, option and restricted stock unit agreements, subscription and registration rights agreements, and revenue participation contracts, which provide further detail on governance and compensation frameworks.
Stock Titan enhances these documents with AI-powered summaries that explain the significance of each filing in clear language. As new 8-Ks, 10-Qs, 10-Ks and other forms become available on EDGAR, they are incorporated so investors can quickly see how developments in obexelimab, orelabrutinib, ZB021 and ZB022, as well as financing and licensing transactions, are reflected in Zenas BioPharma’s official regulatory record.
Zenas BioPharma, Inc. Chief Executive Officer Leon O. Moulder Jr. reported an open-market purchase of 60,000 shares of Common Stock. The shares were bought indirectly through an entity associated with him at a weighted average price of $16.88 per share, with individual trade prices ranging from $16.59 to $16.97. After this transaction, that indirect account held 96,928 shares. As of the same date, he also reported 423,155 shares held directly and 1,786,039 additional shares held indirectly through entities where he may be deemed to have voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest.
Zenas BioPharma, Inc. reported a larger quarterly loss as it ramped up immunology pipeline development while significantly strengthening its balance sheet.
For the three months ended March 31, 2026, the company generated no revenue compared with $10.0 million a year earlier from a prior license payment. Research and development expenses rose to $60.4 million and general and administrative expenses to $16.9 million, driving a net loss of $81.0 million, or $1.46 per share, versus a $33.6 million loss in the prior-year quarter.
Zenas ended the period with $718.5 million in cash, cash equivalents and investments, up from $360.5 million at year-end 2025. The increase reflects net operating cash use of $75.2 million offset by substantial financing activity, including a new $75.0 million senior secured term loan, issuance of $200.0 million of 2.50% convertible senior notes due 2032, a follow-on equity offering of 5,000,000 shares and at-the-market share sales. The company also carries an $84.9 million royalty obligation related to its obexelimab program. Management expects existing liquidity to fund operating and capital needs for at least twelve months from issuance of these financial statements while it advances obexelimab and other autoimmune candidates through clinical development.
Zenas BioPharma, Inc. reported a larger quarterly loss as it ramped up immunology pipeline development while significantly strengthening its balance sheet.
For the three months ended March 31, 2026, the company generated no revenue compared with $10.0 million a year earlier from a prior license payment. Research and development expenses rose to $60.4 million and general and administrative expenses to $16.9 million, driving a net loss of $81.0 million, or $1.46 per share, versus a $33.6 million loss in the prior-year quarter.
Zenas ended the period with $718.5 million in cash, cash equivalents and investments, up from $360.5 million at year-end 2025. The increase reflects net operating cash use of $75.2 million offset by substantial financing activity, including a new $75.0 million senior secured term loan, issuance of $200.0 million of 2.50% convertible senior notes due 2032, a follow-on equity offering of 5,000,000 shares and at-the-market share sales. The company also carries an $84.9 million royalty obligation related to its obexelimab program. Management expects existing liquidity to fund operating and capital needs for at least twelve months from issuance of these financial statements while it advances obexelimab and other autoimmune candidates through clinical development.
Zenas BioPharma, Inc. reported first quarter 2026 results showing no revenue versus $10.0 million a year earlier and a higher net loss of $80.99 million, or $1.46 per share, compared with a $33.57 million loss, or $0.80 per share, in 2025. Operating expenses rose sharply, led by research and development spending of $60.44 million. Cash, cash equivalents and investments increased to $718.55 million as of March 31, 2026, from $360.46 million, after completed public offerings and new debt financing, which the company says extends its cash runway into 2029. Total liabilities increased to $411.85 million, including royalty obligations, a senior secured term loan and convertible senior notes.
Zenas highlighted progress in its autoimmune pipeline, including Phase 3 INDIGO results for obexelimab in IgG4‑Related Disease, ongoing Phase 3 multiple sclerosis trials for orelabrutinib, and Phase 1 development of oral IL‑17 inhibitor ZB021. At its 2026 Annual Meeting, stockholders elected two Class II directors, ratified Ernst & Young LLP as auditor, and the board size was reduced by one following Tomas Kiselak’s previously announced departure.
Zenas BioPharma, Inc. reported first quarter 2026 results showing no revenue versus $10.0 million a year earlier and a higher net loss of $80.99 million, or $1.46 per share, compared with a $33.57 million loss, or $0.80 per share, in 2025. Operating expenses rose sharply, led by research and development spending of $60.44 million. Cash, cash equivalents and investments increased to $718.55 million as of March 31, 2026, from $360.46 million, after completed public offerings and new debt financing, which the company says extends its cash runway into 2029. Total liabilities increased to $411.85 million, including royalty obligations, a senior secured term loan and convertible senior notes.
Zenas highlighted progress in its autoimmune pipeline, including Phase 3 INDIGO results for obexelimab in IgG4‑Related Disease, ongoing Phase 3 multiple sclerosis trials for orelabrutinib, and Phase 1 development of oral IL‑17 inhibitor ZB021. At its 2026 Annual Meeting, stockholders elected two Class II directors, ratified Ernst & Young LLP as auditor, and the board size was reduced by one following Tomas Kiselak’s previously announced departure.
Zenas BioPharma, Inc. insider Leon O. Moulder Jr. and related entities report beneficial ownership of 3,220,880 shares of common stock, representing 5.09% of the class. The stake includes 423,155 shares held directly, 974,758 shares underlying stock options exercisable within 60 days of April 29, 2026, 1,786,039 shares held by Tellus BioVentures, LLC, and 36,928 shares held by a revocable trust.
The filing details long‑running investments in the company’s predecessor, multiple preferred share and note financings, IPO‑related and subsequent option grants, PIPE participation, and open‑market purchases, including 271,000 shares bought between January 7 and April 29, 2026. The reporting persons describe the holdings as for general investment purposes but may increase or reduce their position over time. They also hold registration and piggyback rights under shareholder and PIPE registration rights agreements.
Zenas BioPharma, Inc. reported open-market common stock purchases by entities associated with Chief Executive Officer Leon O. Moulder, Jr. On April 28, 2026, an entity purchased 25,000 shares at a weighted average price of $18.02 per share, and on April 29, 2026, an entity purchased 35,000 shares at a weighted average price of $17.62 per share, for total net purchases of 60,000 shares. Following these transactions, indirect holdings reported for these entities totaled 1,786,039 shares of common stock, while direct holdings reported for Moulder stood at 423,155 shares, and a related revocable trust held 36,928 shares. The filing notes these prices are weighted averages for multiple trades within narrow intraday ranges and that Moulder disclaims beneficial ownership of certain indirect holdings except to the extent of his pecuniary interest.
Leon O. Moulder, Jr. and related entities report updated ownership in Zenas BioPharma, Inc. following recent share purchases. They now beneficially own 3,029,921 shares of common stock, representing 4.794% of the class, including shares held directly, through options, and via Tellus BioVentures, LLC and a revocable trust.
On February 2, 2026, Mr. Moulder purchased 57,000 shares in open-market transactions at prices between $17.69 and $18.14 per share. Between March 30 and March 31, 2026, Tellus purchased 54,000 shares in open-market transactions at prices between $18.195 and $19.58 per share.
Zenas BioPharma director-affiliated investment funds made an open-market purchase of 3,768 shares of common stock at $18.63 per share. After this transaction, entities associated with Hongbo Lu indirectly held 426,736 shares. The filing notes these securities are owned directly by NEXTBio funds, and Lu disclaims beneficial ownership beyond any pecuniary interest.
Fairmount Healthcare Fund II L.P., an entity associated with Fairmount Funds Management, reported an open-market purchase of 150,000 shares of Zenas BioPharma, Inc. common stock at $20.00 per share. After this transaction, the fund indirectly held 2,359,025 shares of Zenas BioPharma common stock.
Fairmount Funds Management LLC acts as investment manager to the fund, and its managers, Peter Harwin and Tomas Kiselak, along with Fairmount, disclaim beneficial ownership of the reported securities except to the extent of any pecuniary interest.
Zenas BioPharma, Inc. chief executive officer–associated entities increased their holdings through open-market purchases of Common Stock. Entities associated with Leon O. Moulder, Jr. bought 20,000 shares on March 30 at a weighted average price of $18.23 per share and 34,000 shares on March 31 at a weighted average price of $19.31 per share, for a total of 54,000 shares. After these transactions, one indirect account held 1,726,039 shares, while another indirect trust account held 36,928 shares and a direct account held 423,155 shares. Footnotes explain that these shares are held by Tellus BioVentures LLC and a revocable trust, where Moulder may be deemed to have voting and dispositive power but disclaims beneficial ownership beyond his pecuniary interest.
Zenas BioPharma, Inc. director-associated investment entities acquired additional common stock in an underwritten public offering. Entities affiliated with Hongbo Lu purchased 75,000 shares of common stock at $20.00 per share, and now hold 422,968 shares indirectly after the transaction. The securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC, with various NEXTBio management entities and Hongbo Lu potentially deemed indirect beneficial owners, subject to a formal disclaimer of beneficial ownership beyond any pecuniary interest.